Question to the Department for Business, Energy and Industrial Strategy:

To ask Her Majesty's Government what assessment they have made of the research into COVID-19 by the MIGAL Research Institute in Israel and the potential effectiveness of their orally-administered vaccine Migvax.

The Vaccines Taskforce is working with experts, as appointed by Kate Bingham as Chair, to assess the range of SARS-CoV-2 vaccine candidates being developed around the world. As part of this assessment, Government will evaluate the MIGAL Research Institute’s orally-administered, viral vector-based vaccine.

Companies and research institutes are welcome to submit proposals to UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR) research calls. Government support is available to prioritise, coordinate and deliver studies which qualify as urgent public health research.